Double-Punch T-Cells take aim at stubborn blood cancers
NCT ID NCT07168291
Summary
This early study is testing a new type of cell therapy for patients whose B-cell lymphoma has come back or hasn't responded to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to attack two specific targets on the cancer cells (CD19 and CD22), and then infuse them back. The main goals are to see if this new therapy is safe and if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
Conditions
Explore the condition pages connected to this study.